Joshua Schafer
Vermogen: 592 264 $ op 31-07-2026
Vermogen: 592 264 $ op 31-07-2026
Joshua Schafer currently works as an Advisor at DRI Healthcare and as Chief Commercial Officer & Executive VP at Zevra Therapeutics, Inc. Formerly, Mr. Schafer was Chairman at Pharnext SA from 2023 to 2024, Independent Director at Shuttle Pharmaceuticals Holdings, Inc. from 2019 to 2025, Director at Shuttle Pharmaceuticals, Inc. from 2017 to 2025, Director at Acer Therapeutics, Inc., VP-Oncology, Therapeutic Area & Global Marketing at Astellas Pharma, Inc., and General Manager-Autoimmune & Rare Disease at Mallinckrodt Pharmaceuticals Ltd. from 2020 to 2022.
Education includes undergraduate studies at the University of Notre Dame and graduate studies including an MBA at Northwestern University.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 03-02-2026 | 62.278 ( 0,11% ) | 592 264 $ | 31-07-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| ZEVRA THERAPEUTICS, INC. | Corporate Officer/Principal | 09-01-2023 |
DRI Healthcare
DRI Healthcare Investment ManagersFinance DRI Healthcare invests in royalty interests in leading pharmaceutical and biotechnology companies, research institutions, universities and inventors. | Consultant / Adviseur | - |
| Bedrijven | Functie | Einde |
|---|---|---|
Shuttle Pharmaceuticals, Inc.
Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops therapies to improve the outcomes of patients receiving radiation therapy for the treatment of cancers | Directeur/Bestuurslid | 01-03-2025 |
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | Directeur/Bestuurslid | 28-02-2025 |
| PHARNEXT SCA | Algemeen Directeur | 28-12-2022 |
Mallinckrodt Pharmaceuticals Ltd.
Mallinckrodt Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Corporate Officer/Principal | 02-11-2022 |
| ACER THERAPEUTICS INC. | Directeur/Bestuurslid | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 10 |
|---|---|
DRI Healthcare
DRI Healthcare Investment ManagersFinance DRI Healthcare invests in royalty interests in leading pharmaceutical and biotechnology companies, research institutions, universities and inventors. | Finance |
University of Notre Dame
University of Notre Dame Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets proprietary prodrugs | Health Technology |
Northwestern University
Northwestern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Astellas Pharma, Inc.
Astellas Pharma, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceuticals and related medical products | Health Technology |
Pharnext SA
Pharnext SA Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops therapies for patients to treat neurodegenerative diseases | Health Technology |
Shuttle Pharmaceuticals, Inc.
Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops therapies to improve the outcomes of patients receiving radiation therapy for the treatment of cancers | Health Technology |
Mallinckrodt Pharmaceuticals Ltd.
Mallinckrodt Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Acer Therapeutics, Inc.
Acer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops and commercializes therapies for serious rare and life-threatening diseases | Health Technology |
Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals products | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau